06-24-00

Express Mail Label No.: ET1/6331606US

Rate of Deposit: June 20, 2002

Attorney Docket No. 15966-599 (CURA-99)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Shimkets and Leach

36C

SERIAL NUMBER:

09/718,321

EXAMINER:

Not Yet Assigned

FILING DATE:

November 22, 2000

ART UNIT:

1645

For:

NUCLEIC ACIDS CONTAINING SINGLE NUCLEOTIDE

POLYMORPHISMS AND METHODS OF USE THEREOF

BOX SEQUENCE

U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

- 1. Copy of Notice to Comply with Requirements for Patent Applications (1 pg.);
- 2. Response to Notice to Comply with Requirements for Patent Applications (1 pg.);
- 3. Sequence Listing

Statement in Support of CRF (1pg.); Compact Disc Copy of the Sequence Listing "CURA-99.app" (1 Compact disc) Electronic Copy of Sequence Listing (1 disk);

- 4. Preliminary Amendment (2 pgs.);
- 5. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No.15966-599 (CURA-99). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Date: June 20, 2002

Ivor R. Elrifi Reg. No. 39,529

Attorney/Agent for Applicants

c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

TRA 1681802v1

Express Mail Label No.: ETT76331606US Date of Deposit: June 20, 2002

ATENT APPLICATION Attorney Docket No. 15966-599 (CURA-99)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

LICANTS:

Shimkets and Leach

SERIAL NUMBER:

09/718,321

EXAMINER:

Not Yet Assigned

FILING DATE:

ART UNIT:

November 22, 2000

1645

For:

NUCLEIC ACIDS CONTAINING SINGLE NUCLEOTIDE

POLYMORPHISMS AND METHODS OF USE THEREOF

BOX SEQUENCE

U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

RESPONSE TO NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

In response to the Notice To Comply with Requirements for Patent Application mailed June 6, 2002, Applicants submit herein a paper copy of the Sequence Listing; Statement in Support of CRF; electronic copy of Sequence Listing (1 diskette); Compact Disc Copy of Sequence Listing "CURA-99.app" (1 Compact disc); and Preliminary Amendment.

The Commissioner is authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 15966-599 (CURA-99).

Respectfully submitted,

Date: June 20, 2002


Ivor R. Elrifi, Reg. No. 39 Attorney/Agent for Applicants

c/o MINTZ, LEVIN

One Financial Center Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

TRA 1681823v1



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER

09/718,321 11/22/2000 Richard A. Shimkets 15966-599 (CURA-99)

Ivor R. Elrifi, Ph.D. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Center Boston, MA 02111 CONFIRMATION NO. 3118
FORMALITIES LETTER

OC000000008247636

Date Mailed: 06/06/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as
indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
of the sequence listing information recorded in computer readable form is identical to the written (on paper
or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE